How Personalized Medicine Became Genetic, and Racial: Werner Kalow and the Formations of Pharmacogenetics by Jones, David Shumway
 
How Personalized Medicine Became Genetic, and Racial: Werner
Kalow and the Formations of Pharmacogenetics
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Jones, D. S. 2013. “How Personalized Medicine Became Genetic,
and Racial: Werner Kalow and the Formations of
Pharmacogenetics.” Journal of the History of Medicine and Allied
Sciences 68, no. 1: 1–48.
Published Version doi:10.1093/jhmas/jrr046
Accessed February 16, 2015 5:02:24 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12718790
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Open Access Policy Articles, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#OAP 
How Personalized Medicine Became Genetic, and Racial: Werner Kalow and the 
Formations of Pharmacogenetics 
 
 
David S. Jones, M.D., Ph.D. 
 
 
Program in Science, Technology, and Society 
Massachusetts Institute of Technology 
 
Department of Global Health and Social Medicine 














77 Massachusetts Avenue, E51-185 
Cambridge, MA 02139 
   1   
Abstract 
 
Physicians have long puzzled over a well-known phenomenon: different patients 
respond differently to the same treatment.  Although many explanations exist, 
pharmacogenetics has now captured the medical imagination.  While this might 
seem part of the broader interest in all things genetic, the early history of 
pharmacogenetics reveals the specific factors that contributed to the emergence of 
genetics within pharmacology.  This paper examines the work of one pioneering 
pharmacologist, Werner Kalow, to trace the evolving intellectual formations of 
pharmacogenetics and, in particular, the focus on race.  Working in the 1950s and 
1960s, Kalow made three arguments to demonstrate the relevance of genetics to 
pharmacology, based on laboratory techniques, analogies to differences between 
other animal species, and appeals to the logic of natural selection.  After 
contributing to the emergence of the field, Kalow maintained his advocacy for 
pharmacogenetics for four decades, collecting more evidence for its relevance, 
navigating controversies about race and science, and balancing genetics against 
other possible explanations of patient variability.  Kalow’s work demonstrates the 
deep roots of the genetic and racial preoccupations in pharmacology.  
Understanding this history can restore attention to other explanations of 
individuality in medical practice, something of increasing importance given the 








 In 1962 Toronto pharmacologist Werner Kalow published 
Pharmacogenetics, the first full length treatment given to a new science that 
explored how genetic traits influenced the safety and effectiveness of medications.
1  
When he presented his work at the New York Academy of Sciences that October, 
the New York Times ran both an article and an editorial about his findings.
2  
Kalow’s book drew interest at the time because it offered an explanation for 
something that increasingly vexed physicians.  Physicians had known and expected 
for millennia that different people responded differently to their ministrations.  
Skilled physicians tailored both diagnosis and therapy to each patient.  With the 
rise of laboratory medicine in the late nineteenth century, however, standardized 
diagnosis and treatment increasingly became the goal of medical thought and 
practice.  Patients’ bodies did not cooperate: idiosyncratic reactions often 
accompanied the introduction of new drugs.
3  Even as physicians achieved 
unprecedented pharmacological capabilities in the decades after World War II, 
their actual experience with treatment outcomes forced them to re-engage with the 
puzzle of patient variability.  How could it be explained?  How could these 
explanations be used to optimize the safety and efficacy of medicine? 
  In the fifty years since Kalow published his book, genetics has come to 
dominate the answers to these questions.  For instance, when Francis Collins and 
Margaret Hamburg, the heads of the National Institutes of Health and the Food and 
Drug Administration, described their vision for “personalized medicine,” their   3   
concerns were exclusively genetic.
4  It is tempting to see pharmacogenetics simply 
as one of many examples of the current popularity of all things genetic.
5  Its actual 
emergence, however, was the result of deliberate strategies to demonstrate the 
existence and relevance of genetic determinants of drug response.  When 
physicians and researchers began to focus on the puzzle of individual variation in 
drug response in the late 1940s, they had recognized three basic modes of 
explanation: heredity, environment, and behavior. Kalow’s work demonstrates how 
one influential researcher made the case that one of these factors -- genetics -- 
deserved special attention. 
  Kalow did not rely on traditional techniques of genetic analysis that traced 
traits across families in order to demonstrate their inheritance.  Instead, he 
developed three different kinds of arguments.  First, he used new techniques of 
pharmacology and enzyme biochemistry, especially spectrophotometry, to quantify 
pharmacological individuality in ways that made difference legible, and eventually 
genetic.  Second, he drew analogies between drug reactions in humans and other 
animal species: pharmacologists’ use of a menagerie of animal models provided an 
influential precedent for thinking about differences between individuals and 
between species.  Third, he appealed to the logic of natural selection and wove 
pharmacologists’ findings into evolutionary narratives that justified the existence 
and relevance of individual difference.  These last two arguments, in turn, 
introduced race into pharmacogenetics and forced pharmacologists to engage with   4   
the politics of race and science, a move with consequences that remain relevant 
today. 
  Kalow was not the only person responsible for the emergence of 
pharmacogenetics in the 1950s, nor was he the only person to make these sorts of 
arguments.  He did, however, play a central role in the consolidation of 
pharmacogenetics as a specific field.
6  Despite this, he has received no serious 
attention from historians of medicine or science.
7  Anthropologists and sociologists, 
who have studied pharmacogenomics,
8 have focused on developments since the 
1990s.
9  This paper offers a partial solution to this gap.  By recovering Kalow’s 
history, it offers insight into the interests and strategies that influenced the 
emergence of pharmacogenetics.  And since his career spanned six decades, from 
its origins in post-war Berlin until his death in 2008, it also reveals important 
aspects of the subsequent development of the field.  Two issues are especially 
relevant. 
  First, Kalow’s work over his long career shows how race emerged as a 
central concern at the origins of the field and has remained an irresistible attraction 
for pharmacologists.  This persistent presence offers a warning to current 
researchers who dismiss concerns about race and medicine by arguing that race-
based prescribing is simply a passing phase on the road to a fully personalized 
medicine.  Second, the current preeminence of pharmacogenetics was not 
foreordained.  Although Kalow and the New York Times had been impressed with 
pharmacogenetics in 1962, the field made slow progress and remained on the   5   
margins of medical science into the 1990s.  Other researchers looked to other 
determinants of drug response, especially the impact of food and environmental 
toxins, and increasingly the problem of non-compliance.  The choices that 
researchers made about which explanations to emphasize shed light on how their 
values and interests shaped the contingent development of a scientific field.
10  An 
appreciation of the complexity of this history offers models for physicians and 
scholars today interested in recovering other ways to personalize medicine. 
 
An Accidental Pharmacogeneticist 
  In 1947, amid the chaos of post-war Berlin, two patients died after receiving 
routine doses of procaine [Novocain], a topical anesthetic.  Hans Herken, a 
professor of pharmacology at the University of Berlin, suspected that endemic 
malnutrition in the devastated city had left the patients with a deficiency of a 
crucial metabolic enzyme.  But he had no proof.  He assigned the problem to a 
young pharmacologist, Werner Kalow.
11 
  Kalow had never intended to become a pharmacologist.  As a medical 
student in Germany and Austria in the late 1930s, he had dabbled in research -- for 
instance, conducting bird surveys on the Baltic coast in the summer of 1937.  
Drafted into the German Navy in 1938, he was allowed to complete his medical 
studies.  He submitted his thesis, on the effects of adrenal extracts on blood 
pressure, in 1941.  While interning at a naval hospital in South Holland in 1942, he 
inadvertently insulted a visiting German admiral.  The admiral promptly assigned   6   
him to be the ship surgeon on a blockade runner, a degrading and dangerous 
assignment.  After several nearly catastrophic attacks by allied bombers, the ship 
escaped European waters and delivered its cargo, a hydroelectric generator, to 
Japan.
12 
  The return trip did not go as well.  The Allied blockade of Europe stranded 
the crew in the Japanese Empire until 1944.  Then a United States destroyer sunk 
the ship off the coast of Brazil and took the crew as prisoners of war.  Kalow ended 
up at a large POW camp, Papago Park, near Phoenix, Arizona.  This proved to be a 
blessing.  Since the war had left stateside hospitals short-staffed, the Army recruited 
Kalow to work as an intern, allowing him to complete his medical training while a 
POW.  When he returned to Germany in 1946, he tried his hand at clinical work.  
He quickly decided to seek a career in research instead.  His choice of specialty 
was a political one.  Most of the University of Berlin, including the Pathology 
Department, had ended up in the Russian sector.  The Pharmacology Department, 
however, had been bombed during the war and was rebuilt in the American sector.  
Kalow chose to stick with the Americans and become a pharmacologist.  He began 
his work in January 1947.
13 
  Kalow’s initial work took up a basic question in pharmacology: what 
happens to a drug when it enters the body.  He completed a study of one poison, 
phenylethanolamine.
14  When the two patients mentioned above died after a 
typical dose of procaine, Herken asked Kalow to figure out what had happened.  
Researchers in the United States, led by Bernard Brodie, had recently identified a   7   
specific enzyme, procaine esterase, that metabolized this drug.  Had malnutrition 
somehow altered its function?  Kalow performed studies on human serum to find 
out.
15 
  The work was difficult.  Kalow had no way to measure directly the level of 
an enzyme in serum.  He could, however, measure drug levels with a 
spectrophotometer.
16  With this device, he could shine a light on a sample and 
analyze the absorption spectrum.  As an enzyme metabolized the drug, the 
concentration fell and the absorption spectrum changed.  The rate of change of 
concentration correlated with the level of enzyme activity.  However, to do this 
Kalow needed a roomful of equipment, including a photomultiplier tube donated 
by the U.S. Army, and a physicist to generate the needed wavelengths of ultraviolet 
radiation.
17  Kalow persevered with the device and his work caught the attention of 
a delegation of visiting American scientists.  One offered him a fellowship at the 
University of Pennsylvania, where he joined a team working on cardiac 
physiology.
18 
  On arriving in Philadelphia in late 1949, Kalow found a new device, a 
Beckman DU Quartz Spectrophotometer.
19  This desktop box could do on its own 
what had required a roomful of equipment and a physicist in Berlin.  Able to work 
more quickly, Kalow showed that one enzyme, serum cholinesterase, metabolized 
many local anesthetics, including procaine and dibucaine, as well as 
acetylcholine.
20  Tutored in enzyme biochemistry by Britton Chance, Kalow 
conducted sophisticated studies of enzyme competition and inhibition.  Reaction   8   
rates depended on how tightly enzymes bound their substrates.  This, in turn, 
depended on enzyme structure.
21 
  Offered a faculty position in the Department of Pharmacology at the 
University of Toronto in 1951, and eager to avoid being drafted a second time-- 
this time into the United States Army for the Korean War -- Kalow moved once 
more.  He worked on a variety of projects at first.  One project, conducted with the 
Toronto police, used a Harger Drunkometer to quantify alcohol levels in 
intoxicated drivers after accidents.
22  He also continued his more traditional work 
in pharmacology and used a spectrophotometer to study curare and procaine.
23 
  Kalow soon returned to his true passion, cholinesterase.  During the war, a 
Toronto team had used a cumbersome but precise gasometric technique to study 
enzyme activity.  When Kalow demonstrated his spectrophotometer, they were 
impressed by its speed and simplicity.  But they wondered whether it would also 
work on the rare patients that they had found with low cholinesterase activity.
24  
This had become a problem of growing clinical interest.  Donald Gunn, a 
psychiatrist at the Ontario Hospital in New Toronto, had recently begun using 
succinylcholine as a paralyzing agent for electroconvulsive therapy.  The drug’s 
fleeting action was well suited for the quick procedure.  Since Gunn’s patients 
received multiple treatments over weeks or months, it was easy to study their 
reactions to varied doses of the drug (Figure 1).  Gunn had already found two 
patients who experienced prolonged apnea.  One poor man remained paralyzed, 
while awake, for 45 minutes.  Gunn and Kalow began collaborative studies, taking   9   
118 patients through ECT treatments with doses of succinylcholine ranging from 30 
to 1000 mg.
25  Results showed that the problem was not low enzyme 
concentration, but low enzyme affinity for its substrates.  Since affinity depended 
on enzyme structure, and enzyme structure depended on amino acid sequence, the 
difference must have been genetic.  When he presented his findings at the 
Canadian Physiological Society in October 1954, it made front-page news.
26 
  Kalow and Gunn expanded their studies to include 443 students, 346 
laborers, 1228 people tested for syphilis, and 2442 psychiatric patients.  In one 
extreme case, a psychiatric patient experienced 157 minutes of complete paralysis 
from a dose that generally produced just five to ten minutes of paralysis; it took a 
full eight hours for the patient to recover respiratory function.
27  Kalow pursued 
large scale testing so that he could be confident in his results before publishing.  
The delay cost him dearly: he got scooped.  In July 1956 a London group published 
in Lancet a report on a family with low cholinesterase activity.
28  Kalow felt the 
sting: “Such little incidents can be damaging to a scientist who thereby loses 
priority in public view -- even if not in his or her own mind.  Lesson to a scientist: 
always publish as fast as you can.”
29  Kalow drafted a brief account of his own 
work and published it as a letter in Lancet that September.
30  He worked quickly 
and published detailed accounts of many aspects of his work.  While the London 
group had looked only at phenotype, distinguishing normal from atypical activity, 
Kalow’s quantitative analyses using enzyme inhibitors revealed an intermediate   10   
level of activity.
31  Studies of seven families in Ontario, Quebec, New York, and 
Michigan confirmed a Mendelian pattern of inheritance. 
  It was not just these specific experimental results that fueled Kalow’s interest 
in genetics.  The social-scientific contexts of his work made genetics a promising 
result for an aspiring young scientist.  When Kalow arrived in Toronto in 1951, 
genetics remained on the periphery of medical science.  This changed over the 
next decade, prompted by rapid discoveries in the emerging field of molecular 
biology.
32  Recognizing the opportunity, Kalow realized that he needed to learn 
more about the new science.  He apprenticed himself to the local professor of 
genetics, Norma Ford-Walker.  He participated in a 1959 Ciba Foundation 
Symposium on the Biochemistry of Human Genetics where he joined notables 
including Luca Cavalli-Sforza, Salvador Luria, Joshua Lederberg, Macfarlane 
Burnet, and James Neel.
33 
  Kalow read widely and learned much that seemed relevant to 
pharmacology.
34  Genes controlled antibiotic resistance in bacteria, chemotherapy 
resistance in tumors, and pesticide resistance in insects.  One family of dogs, like 
his first patients in Berlin, had died from routine doses of procaine.  He read about 
two recently described pharmacologic variants in humans.  Some patients 
developed hemolytic anemia after primaquine prophylaxis for malaria.  Others 
suffered hepatitis or peripheral neuritis after tuberculosis treatment with isoniazid. 
  Kalow also found inspiration in the old insights of Archibald Garrod about 
human metabolic variation.
35  Garrod, who studied cases of familial alkaptonuria,   11   
wrote in 1902 that metabolic variations between humans should be no more 
surprising than the familiar anatomic variations.
36  Scientists working for the League 
of Nations grappled directly with this problem as they worked to standardize 
measures of the potency of hormones and realized that drug response varied from 
person to person.
37  The existence of genetic influences on drug response seemed 
obvious, appropriate, and relevant. 
  Kalow compiled his research and literature review into his 1962 
Pharmacogenetics.  His readers could find everything from a primer about the 
genetics of bacteria, insects, and mammals, to discussions of abnormal drug 
reactions caused by metabolic variations, his own work on serum cholinesterase, 
and why asparagus altered the aroma of urine in some people but not others.  
Although he knew that these were obscure topics, he saw much promise in the 
field: “One may ask whether the field of investigation here called 
pharmacogenetics is the end of a road or the beginning of a new one.  There are 
many signs which suggest that the number of established instances of a hereditary 
control of pharmacologic responsiveness will considerably increase in the near 
future.”
38 
  Thoroughness again cost him priority.  As he worked on this long project, 
American geneticist Arno Motulsky published a 1957 article in the Journal of the 
American Medical Association that described the intersection of pharmacology and 
genetics, suggesting that adverse drug reactions could arise from “otherwise 
innocuous genetic traits or enzyme deficiencies.”
39  German pharmacologist   12   
Friedrich Vogel coined the term “pharmacogenetics” in 1959.  Despite this, 
Kalow’s book still generated considerable interest.
41  When he presented his work 
at the New York Academy of Sciences in October 1962, it was picked up by the 
New York Times.  As described in an editorial, “differences in genetic make-up 
between individuals make for radically different degrees of risk in taking drugs.”
42  
With the thalidomide scandals in 1961 and the Kefauver hearings from 1959 to 
1962, there was great interest in anything that might improve drug safety. 
 
The Technology of a Genetic Argument 
  It is worth looking closely at how Kalow made his case that individual 
variation in drug response was under genetic control, and how his strategies related 
to broader developments in the history of genetics and molecular biology.  Kalow 
developed three arguments in parallel, based on the technology of biochemical 
enzymology, on an analogy to animal models, and on an appeal to the intuitive 
logic of natural selection. 
  The first argument depended on his laboratory practice.  Kalow collected a 
blood sample and spun it down to isolate the serum.  He diluted the serum and 
added a substrate, benzoylcholine.  Using a spectrophotometer, he shined a light 
across the sample and recorded the absorption spectrum in order to measure 
substrate concentration.  The rate of change of concentration over time measured 
enzyme activity.  This was one of many ways that pharmacologists employed 
spectrophotometers in their research in the 1950s.
43  Kalow, however, developed a   13   
special trick.  He took a second sample and added both the substrate and an 
inhibitor -- dibucaine.  By repeating the measurements, he could measure inhibited 
enzyme activity.  He called the degree of inhibition caused by dibucaine, 
expressed as a percentage, the “Dibucaine Number” (DN).  Calculated in this 
manner, the DN did not depend on the concentration of the enzyme in the serum.  
Instead, it depended on something more fundamental, the affinity of the enzyme’s 
binding sites for different substrates.  Binding affinity, in turn, depended on the 
physical structure of the enzyme.  Since enzyme structure depended on its amino 
acid sequence, the structure and the resulting affinity and enzyme function had to 
be under genetic control.  The DN was, as Kalow concluded, “genetically 
determined.”
44 
  Kalow’s experimental method made an occult process legible and reduced it 
to a single number for each patient and to a graph of DN distribution in the 
population of patients studied.
45  This facilitated comparisons between individuals 
and between groups and enabled the construction of arguments about difference.  
Kalow’s methods produced a very different argument for genetic causation than the 
traditional method of tracing a trait through a family tree.  Genetic research, from 
Mendel’s peas to Davenport’s eugenic family histories or Morgan’s fruit flies, had 
relied on intuitive notions of heritability.
46  If a trait bred true from one generation 
to the next, it must be heritable which meant, by the mid-twentieth century, that it 
was carried by a gene.
47  Such studies of human genetics depended on careful 
reconstruction of family lineages.  Kalow’s method, in contrast, allowed arguments   14   
to be made about genetics based only on only on the study of living, unrelated 
individuals.
 48 
  The technique, however, did allow Kalow to make more familiar kinds of 
genetic arguments.  For instance, when Kalow plotted the DN of research subjects 
and their families, he found a trimodal distribution (Figure 2).  Most people had a 
DN between 70 and 90.  Others ranged between 40 and 70.  A very few 
individuals had DN’s of less than twenty.
49  Kalow read this distribution as 
evidence of two basic levels of activity, high and low, caused by two different 
enzyme forms, active or not, generated in turn by two different genetic alleles.  He 
interpreted intermediate activity as evidence of heterozygosity: individuals with 
one active and one inactive allele.  DN, the product of a complex analysis of 
spectrophotometry and enzyme biochemistry, appeared to be a conventional 
Mendelian trait.  This kind of argument about intermediate forms as evidence of 
Mendelian inheritance had been recently and famously made by both Linus 
Pauling and James Neel for the inheritance of sickle cell anemia.
50 
  The parallels between Kalow’s work and that of Neel and Pauling raises 
important questions the place of pharmacogenetics in the development of 
molecular biology.  Historians of molecular biology have focused on several 
stories: how researchers studied the relations of nucleic acids and proteins to the 
flow of genetic information, and how they deciphered the structure of proteins and 
nucleic acids in order to understand their function.
51  This research depended 
significantly on the import of new laboratory technologies from the physical   15   
sciences into the life sciences, especially electron microscopes, x-ray 
crystallography, ultra-centrifuges, radioisotope probes, and spectrophotometry.
52  
But there were other important topics for which researchers attempted to unlock 
the molecular secrets of life.  The Rockefeller Foundation, for instance, funded 
research on photosynthesis and bioenergetics, as well as on enzyme biochemistry 
more broadly.  Much of this work relied on spectrophotometry.
53  The researchers 
themselves saw the field broadly.  G. Montalenti, in the opening remarks of the 
Ciba Foundation’s 1959 symposium described valuable work on both structural 
analysis of genes and chemical analysis of gene expression.
54  The latter is where 
Kalow’s work fit in. 
  Kalow was not interested in the specific structure of cholinesterases or in the 
genes responsible for them.  Instead, he focused simply on describing their function 
and variations.  While this might seem peripheral compared to the work on the 
double helix that has received so much attention, molecular biologists in the 1950s 
were quite interested in his work.  Kalow, for instance, presented his work on 
cholinesterase variants at the 1959 symposium.  Other speakers emphasized the 
importance of work on drug metabolism.  L.S. Penrose, who directed the Galton 
Laboratory at the University of London, described the value -- to geneticists -- of 
the identification of drug metabolizing variants: “Any gene may be abnormal in a 
particular environment.  In this connexion, it is noteworthy that entirely 
unsuspected genetical sensitivities to artificial new environments produced by 
synthetic drugs have been brought to light.”
55  Luca Cavalli-Sforza similarly   16   
described the interest of “genetical analysis” of drug response variants.
56  Kalow 
had a particular approach to genetics, one grounded in the concerns and 
techniques of medical pharmacology.  His methods, however, allowed him to 
make powerful arguments about the genetic determinants of drug metabolism and 
engage the burgeoning community of molecular biology. 
 
Animal Pharmacology and the Argument by Analogy 
  Even as Kalow explored the details of enzyme function and its genetic 
determinants, he also looked to the level of organisms and species in order to make 
claims about the relevance of genetics.  When Kalow began his work in 
pharmacology in 1947, he quickly learned that different species responded 
differently to drugs and poisons.  His initial study of the poison 
phenylethanolamine found markedly different effects in different animal species.
57  
When he moved on to procaine, he learned that it too had species-specific effects.  
Long used as a local anesthetic in humans, procaine had recently generated 
attention as a doping agent in horse racing: in horses, it acted as a central nervous 
system stimulant.
58  His work revealed a possible basis for this effect: human and 
equine procaine esterases had different affinities for different substrates.  Humans, 
for instance, metabolized procaine 16-times faster than horses did.
59  This interest 
in species differences followed Kalow to North America.  When he studied cardiac 
physiology in Philadelphia, his results differed from those reported by another 
team.  He suspected that inter-species variation explained the discrepancy: “We   17   
have no explanation for the divergence of our findings (vasodilatation) from those 
of MacDowall (vasoconstriction) other than a species difference since his 
experiments were made on cats and ours on dogs.”
60  When he moved to Toronto 
and began studies on curare, he found that its potency varied significantly between 
frogs and mammals.
61  During his initial years there, he had to earn extra money by 
testing horses at a local racetrack for morphine.  Like procaine, it had stimulant 
effects in horses and had been banned as a doping agent.
62 
  Intrigued by these results, he surveyed the literature in search of other 
examples of differences in drug response between animals.  He found many.  The 
story began with rabbits.  In 1852 a Viennese scientist noted that a population of 
rabbits survived on a diet of belladonna leaves.  This was notable because 
belladonna, also known as deadly nightshade, contained atropine, an alkaloid that 
would be lethal to most mammals.  Follow up studies in 1910 found that certain 
rabbits, but not all of them, possessed an atropine esterase that rendered 
belladonna harmless.  Most scientists dismissed these findings.  Kalow later 
speculated that “the time was not ripe for an acceptance of the idea that there are 
pharmacogenetic differences between various stocks of rabbits.”
63  Subsequent 
study, however, confirmed the existence of the atropine esterase that allowed 
rabbits to thrive in fields of belladonna that would have left other animals wide-
eyed or dead.  A 1943 study, for instance, found that roughly half of 181 rabbits 
tested possessed the enzyme.  The prevalence varied between rabbit populations.  
While “a New Zealand White race” lacked the esterase completely, other strains   18   
had it in many individuals, and still others, including “a pure chincilla race,” 
produced both enzyme-possessing and non-enzyme-possessing bunnies.  This 
pattern “suggests the existence of racial differences,” at least among rabbits.
64 
  Kalow found many other relevant examples.  Horses, humans, rabbits, and 
monkeys all had different levels of esterase activity; goats and cows had none.
65  
Dogs were poor acetlyators.  Sheep lacked glucose-6-dehydrogenase.  Morphine 
response differed radically: “Some people always react to morphine like cats--with 
excitement; most people react like dogs and become sedated.”
66  Species 
differences were most obvious with insecticides.  The goal was to find chemicals 
that killed insects with minimal toxicity to humans and other mammals.  Evidence 
of inter-species differences in drug metabolism posed a challenge for scientists who 
wanted to extrapolate from animal research to human use.  As Kalow warned, “the 
fate of the drug may vary substantially from species to species, and conclusions 
reached by studying the fate of the drug in other species are not directly applicable 
to man.”
67 
  Kalow also found evidence of variation at a finer level, between strains of 
the same species.  Only certain rabbit races had atropine esterase.  Harvard rats 
could tolerate a 44-mg dose of thiourea, but Hopkins rats could only tolerate 4 mg.  
This was not a function of Harvard stalwartness: some wild-type Norway rats could 
survive 1340 mg.
68  When a laboratory catastrophe in Bar Harbor exposed 
countless mice to chloroform, mortality rates ranged between zero and 74% across 
different strains.  Susceptibility to alcoholism varied as well.  While many rats   19   
strains avoided alcohol, “one strain easily became drunkards when given a 
vitamin-deficient diet.”
69  As Kalow later wrote, “The more precisely one measures 
the effects of a drug in laboratory animals, the more likely one is to find differences 
between strains.”
70  To the extent that differences between (and within) animal 
species reflected genetic differences, then such species-specific differences in drug 
metabolism, especially among laboratory animals raised in controlled 
environmental conditions, must have reflected genetic differences. 
  Kalow was not alone in his interest in the precedent offer by species and 
subspecies variation in drug response.  When Motulsky published his initial 
discussion of genetics and drug reactions in 1957, he admitted that no one had yet 
made a convincing case that genetic differences in drug metabolism existed in 
humans.  However, he too knew about the story of rabbits and atropine esterase, 
and about strains of mice that were resistant to insulin.  He described how 
“Qualitative differences between species also exist,” with morphine, for instance, 
causing hyperexcitability in horses and cats, but not in humans.
71  Brodie had 
similar interests.  In his introduction to the First International Pharmacological 
Meeting, held in Stockholm in 1961, Brodie noted that “Much work on the 
problem of species and strain differences remains to be done … Is it possible that 
enzymes which appear to be the same in two species are actually different?”  Like 
Kalow, he had been struck in his own work by marked differences in drug toxicity 
between species: “I well remember our surprise when Dr. Axelrod and I found that 
phenacetin, an unusually non-toxic drug in man, was quite toxic in dog due to the   20   
accumulation of the methemoglobin-forming free amine in this species.”
72  
Although all were aware of species-level variation, it was Kalow who took the step 
of compiling an exhaustive review of existing knowledge of the differences in drug 
metabolism between species of bacteria, insects, and mammals, as well as between 
subspecies and strains of mammals.  To the extent that metabolism, like anatomy, 
was under genetic control, the pervasiveness of metabolic variation demonstrated 
the relevance of pharmacogenetics. 
 
Natural Selection and an Argument Based on Intuition 
  The ubiquity of drug metabolizing variants across the animal kingdom raised 
an obvious question: why was that the case?  As Kalow recognized the prevalence 
of atypical esterases in 1954 and thereafter, he began to wonder about the meaning 
of the finding.  Cholinesterase initially had no known function other than its impact 
on drug metabolism.  Since it seemed impossible that drug metabolizing enzymes 
had evolved eons ago simply to be on hand once doctors developed 
pharmaceuticals, Kalow pondered what their physiological role had been in a 
world before procaine and succinylcholine.  When his initial research suggested a 
higher incidence of atypical activity in psychiatric patients, Kalow suggested that 
cholinesterase played a role in neurophysiology and the pathophysiology of mental 
illness.
73  Subsequent research, however, did not bear this out.
74  His next 
hypothesis was more prosaic.  Perhaps cholinesterase variants mediated response   21   
to potential environmental toxins, specifically some found in potatoes and 
asparagus.
75 
  Kalow’s argument here paralleled one that was being made with increasing 
frequency in the 1950s and 1960s: that genetic variations existed because of 
evolutionary selective pressures on human and other animas.  A.C. Allison had 
famously made the case in 1954 that sickle cell trait persisted in tropical 
populations because it provided selective advantage in settings of endemic 
malaria.
76  Kalow’s examples, though less dramatic, followed the same logic.  The 
enzymes that metabolized drugs must have evolved to manage various 
environmental toxins, especially those from food.  Since different animals evolved 
in different environments, they evolved different toxin metabolizing repertoires.  
When animals lived in the same environment, especially in controlled laboratory 
conditions, these differences became latent, only to be unmasked when exposed to 
drugs and other chemicals. 
  Some researchers were cautious when making these arguments.  Montalenti 
had been puzzled by the way in which medical treatments had revealed 
unsuspected human variations: “it is noteworthy that entirely unsuspected genetical 
sensitivities to artificial new environments produced by synthetic drugs have been 
brought to light.”
77  While he was not exactly sure what had maintained those 
alleles in the population, he suspected that the answer lay in natural selection: “it is 
reasonable to assume that any gene found persistently in human populations is 
likely to be in a fairly stable state with respect to selective forces.”
78  Motulsky,   22   
citing the example of sickle cell and malaria, also suspected that “some selective 
advantage” maintained drug metabolizing variants in populations.
79 
  Others were more assertive.  Brodie, whose work identified the liver 
enzymes responsible for drug metabolism, was more confident in his speculation: 
“One cannot help asking whether the latent capacity of these enzymes developed 
in the course of evolution to enable the organism to respond to the sustained 
presence of large amounts of foreign organic compounds ingested in food.”
80  
Drugs were simply examples “of a class of compounds to which the organism has 
been exposed over the ages.”
81  Differential exposure over evolution had led to 
differential genetic capacity.  Kalow’s thought closely paralleled Brodie’s.  As 
Kalow later wrote: “Since drugs are part of the human environment, it is natural to 
encounter hereditary factors that affect the responsiveness of the human organism 
to drugs, and one should find these factors in all forms of life which are 
appropriately studied.”
82 
  Kalow’s interest in the evolutionary argument persisted throughout his 
career.  For instance, in June 1997 evolutionary theorist Stephen Jay Gould 
published an extensive critique “ultra-Darwinian fundamentalists” who believed 
that natural selection was responsible for every complex trait.
83  Gould argued for a 
more pluralistic vision, in which natural selection was the most important of 
several mechanisms that generated new traits.  This triggered an angry exchange 
with psychologist Steven Pinker about the merits of evolutionary psychology.
84  
Kalow and a colleague entered the fray, offering pharmacogenetics as an example   23   
of the non-adaptationist mechanisms that Gould favored.  A pharmacogenetic trait 
could emerge and persist, not because it conferred current selective advantage to 
an individual, but because it provided potential advantage to the species should the 
environment change: “they constitute a sort of biological insurance policy for the 
species, rather than for the individual.  Like Professor Gould’s ‘spandrels,’ they 
have no particular use when they arise, but may acquire a use later on.”
85  Gould 
replied by tweaking their interpretation and suggesting that natural selection might 
favor “more variable species” (i.e., ones with more variable drug metabolism 




The Racialization of Pharmacogenetics 
  The analogy to species differences and the appeal to evolutionary logic both 
served to naturalize and justify genetic difference.  They also naturalized racial 
difference: to the extent that different races had experienced different foods and 
environmental toxins, they too should have developed differently tuned drug 
metabolizing enzymes.  This turn to race, at the very origins of pharmacogenetics, 
can be seen clearly in Kalow’s work. 
  Kalow’s interest in species and subspecies differences extended to studies of 
humans.  As he surveyed the literature in the late 1950s, he found many reports 
about human racial differences in drug response.
87  H.A. Paskind, working in 
Chicago in the 1920s, showed that whites and blacks had different hemodynamic   24   
responses to atropine.
88  K.K. Chen and Edgar Poth, working at Hopkins, found that 
whites, blacks, and Asians had different mydriatic responses to cocaine, 
euphthalmine, and ephedrine.
89  Meanwhile, British and German researchers, 
working in Africa and Asia in the 1920s, observed that some Asians and Africans 
experienced hemolytic anemia after primaquine treatment for malaria; Europeans 
did not.
90  During World War II, US Army physicians recognized a similar risk of 
hemolytic anemia among African American soldiers.  In 1954 researchers traced 
this risk to low activity of a specific red blood cell enzyme, glucose-6-
dehydrogenase.
91  Continuing work found high rates among Negroes, Orientals, 
Sardinians, and Greeks, but low rates in Europeans, Ashkenazi, and Peruvian 
Indians.
92  The side effects of isoniazid also had a racial distribution.  As 
tuberculosis treatment campaigns took isoniazid worldwide, clinicians observed 
two sorts of side effects, depending on patient’s acetylation capacity.  Slow 
acetylation carried a risk of peripheral neuritis, while fast acetylation led to 
hepatitis.  Chinese, Japanese, and Eskimos were likely to be fast acetylators, 
Sudanese slow, and Caucasians and African-Americans mixed.
93  Kalow heard 
rumors that operative mortality varied between populations, with dark skinned 
patients in the United States, Jamaica, or Fiji at highest risk.
94  Racial differences in 
the ability to taste specific substances also existed, with high rates of non-tasters of 
phenylthiourea among Europeans and Asians, but low rates in Africans and 
American Indians.
95    25   
  Motulsky was similarly aware of how drug metabolizing traits varied across 
ethnic groups.  He began his 1957 discussion with the unusual prevalence of 
primaquine-induced hemolytic anemia in African Americans.  He suspected that 
many of these ethnic differences reflected underlying genetic differences: “any drug 
reaction that is more frequently observed in a given racial group, when other 
environmental variables are equal, will usually have a genetic basis.”
96  Even after 
the 1950 UNESCO statement on “The Race Question,” that condemned the many 
myths and misuses of race, race remained an appealing analytic category for 
medical researchers.
97 
  Although Kalow knew about these varied examples, he had limited personal 
experience with racial variation.  While stranded in the Japanese Empire during the 
war, he had encountered the “exotic” orient.  His travel throughout Japan, China, 
Vietnam, and Korea, was “a truly broadening experience”: “To us as newcomers, 
the first overwhelming impression was the strangeness of the country: the exotic 
faces, the traditional dress, the houses, the streets.  It was all so different from 
home.”
98  Toronto in the mid-1950s offered a more limited sample of research 
subjects.  He tested people from Canada, Great Britain, Poland, Ukraine, 
Yugoslavia, Russia, France, Italy, Austria, Germany, Hungary, and “31 other 
countries (mostly European).”
99  When he found no differences between groups, he 
blamed the homogeneity of his research population: “The great majority of all 
investigated persons were of European extraction.  There was no evidence for a 
different incidence of atypical esterase among Europeans, or between Europeans   26   
and North Americans, or between religious groups.”
100  Even these limited studies, 
however, did occasionally yield a tantalizing lead: “We had an opportunity to 
observe atypical esterase in one Arabian family and one Persian.”
101  Kalow’s 
concern that the limited geographic diversity of his research subjects would limit 
their pharmacogenetic diversity reflects what was then a significant assumption 
about the distribution of human genetic diversity. 
  In his writings about these sorts of group differences, Kalow did not 
distinguish between species, subspecies, and races as categories of different 
ontological status.  This was a question that scientists had debated since the 
eighteenth century.  Beginning in the 1960s, biologists increasingly tried to enforce 
a distinction: species are a fundamental unit of biology, while subspecies and races 
are arbitrarily defined.
102  In this strict definition, the existence of species-level 
differences ought not provide a compelling analogy for the existence of subspecies-
level differences.  Kalow, however, lumped the categories together, for instance 
offering explanations for “the different responses of breeds, strains, races, 
species.”
103  Subspecies variations, such as those between white and chincilla 
rabbits or between Harvard and Hopkins rats provided a more credible precedent.  
However, it remained unclear to what extent differences between inbred laboratory 
strains might parallel the natural variations between human populations. 
  Another point becomes relevant here.  Scholars have described how model 
organisms -- fruit flies, mice, viruses, and others -- standardized biological research 
and facilitated the development of modern genetics.
104  Kalow’s work demonstrates   27   
something different: the importance of lack of standardization.  He and the 
researchers whom he read did not rely on one or a few animal models.  Instead, 
they worked with a menagerie of different ones -- mice, rats, cats, dogs, horses, and 
various strains of each.  This diversity became relevant for Kalow’s analyses.  
Seeing heritable pharmacogenetic differences across so many different subspecies 
and species, Kalow expected that comparable racial and ethnic differences existed 
in humans. 
  Researchers’ interest in race and pharmacology had real consequences.  At 
the First International Pharmacological Meeting in 1961, where Kalow played an 
active role, Brodie posed the basic challenge: “An ever-recurring question is which 
species is closest to man in metabolizing drugs?  One might indeed ask ‘What 
man?’, since individuals of homo sapiens metabolize a given drug at vastly different 
rates.  In fact this biochemical variability is a major difficulty in evaluating drugs in 
man.”
105  Kalow worried about this same problem: “gene frequencies vary between 
populations.  This means that a drug that has been shown to be safe in one 
population is not necessarily that safe in another racial group.”
106  Pharmacologists 
could not extrapolate between human populations, let alone between mammalian 
species, in their studies of drug safety and efficacy.  When the New York Times 
covered Kalow’s 1962 presentation at the New York Academy of Sciences, both 
the article and the accompanying editorial highlighted the problem of the 
differential susceptibility of human populations to adverse consequences of 
drugs.
107   28   
 
Expanding the Evidence Base 
  Kalow’s research, literature reviews, and rhetorical strategies all contributed 
to the consolidation of pharmacogenetics in the late 1950s and early 1960s.  His 
work, however, did not stop there.  Instead, over the next forty-five years he 
continued to make the case for pharmacogenetics.  As he did this, he remained 
engaged with two central problems: the politics of race in science, and the 
challenge of assessing the relative importance of genetics and other factors. 
  Kalow’s advocacy of the relevance of genetics to pharmacology and 
medical therapeutics faced some daunting challenges.  When Kalow published 
Pharmacogenetics in 1962, scientists knew of six human drugs metabolizing 
enzymes with significant polymorphisms.  Most of these did not influence drugs 
used widely in North America.  Over the next seventeen years researchers 
identified only two additional variants.
108  Given these constraints, Kalow worked 
on three fronts to make the case for the relevance of genetics to pharmacology and 
therapeutics. 
  First, he remained on the lookout for any evidence of significant 
pharmacogenetic variants.  Collaborating with anesthesiologist Beverly Britt he 
helped characterized one of the most terrifying ones: malignant hyperthermia.  In 
the 1960s anesthesiologists described a new syndrome in which patients developed 
fatal hyperthermia (with fevers over 110°) and muscle rigidity during routine 
anesthesia with halothane and succinylcholine.  Clinical studies quickly revealed   29   
that susceptibility ran in families, suggesting a genetic basis.
109  Because this was a 
catastrophic reaction to a widely used drug, Kalow called on all physicians to 
search family histories for anesthetic complications before taking patients to 
surgery.  Racial and species variations again seemed relevant.  Studies in fourteen 
families at the Hospital for Sick Children in Toronto found a frequency of 1:14,000, 
“All three major racial groups -- Oriental, Negro, and Caucasian -- were 
involved.”
110  Research in rabbits, rats, dogs, chickens, and pigs revealed a similar 
syndrome in pigs, but with a different underlying pathophysiology.
111 
  Second, Kalow continued to publish review articles that emphasized the 
relevance of pharmacogenetics.
112  Improvements in screening technologies 
facilitated this work.  During the 1960s, researchers led by Harry Harris at the 
Galton Laboratory in London learned how to use electrophoresis to screen for 
enzyme variants.  They found person-to-person differences in one-third to one-half 
of all enzymes.  Kalow recognized the implications of this: “If his figures are 
representative, well over half of the human enzymes could be genetically variable.  
This should have an impact on concepts of human variation in response to 
drugs.”
113  Parallel work by Elliott Vesell at the National Institutes of Health used 
twin studies to reveal the impact of genetic variation of the metabolism of widely 
used drugs, with heritability ranging between 87% and 99%.
114 
  Third, Kalow continued his own research on esterases.  Spectrophotometers 
gave way to inhibitor-impregnated filter paper that allowed Kalow’s team to screen 
200 samples overnight.  The new technology enabled broader population studies.    30   
An initial study of 6500 Brazilians found intermediate cholinesterase activity in 
2.8% of the sample.
115  Kalow could compare this to findings by other researchers 
from other populations.  He found low rates of atypical forms in Australian 
Aborigines (1%) and Brazilians (2.8%), and higher rates in Canadians (3.8%), 
Berbers (4.0%), Jews (6.3%), and Czechoslovakians (8.5%) (Figure 3).  His initial 
interpretation emphasized homogeneity: the Brazilian result added “one more 
piece of evidence confirming the remarkable similarity of the frequencies of the 
E1u and E1a alleles among populations in the world.”
116  However, as research 
accumulated in the 1970s, populations seemingly diverged, with atypical 
cholinesterase found in 1:3000 Caucasians, 1:100,000 Negroes, and 1:400,000 
Orientals.
117 
  The accumulating evidence of pharmacogenetic variants garnered attention 
from health authorities.  In 1964 the World Health Organization had established a 
study group on drug efficacy and safety.  This group was interested from the outset 
in the racial variations in responses to primaquine and isoniazid.
118  In 1970 the 
WHO Advisory Committee for Medical Research convened a scientific group on 
the role of genetic factors and appointed Kalow as chair.  He argued that the 
existence of racial variations in drug metabolism created a potential public health 
problem: “Since most drugs are at present initially tested on limited populations, 
interethnic variability could be of practical importance as well as academic interest 
when the drugs are later used on a world-wide scale.”
119  With its existing drug 
monitoring program, which had documented 80,000 adverse reactions in fifteen   31   
countries over four years, Kalow felt that the WHO was well positioned to conduct 
population-based studies for “elucidating ethnic variability in the metabolism of, 
and in responses to, drugs.”
120 
 
Rhetoric and Politics of Genetics and Race 
  As racial variations attracted increased attention, social and political 
tensions became evident in Kalow’s work.  He knew from some initial work on 
pharmacogenetics and psychopharmacology that certain kinds of genetic 
arguments could be controversial.  As he wrote in 1975, “Any suggestion that the 
mind can be subject to the same variations as are height, eye colour, etc., will be 
understood by some people and yet provoke a great outcry in the general 
populace.”  Mention of a genetic basis for behavior “creates many emotional 
problems.”  The situation was especially acute for genetics and race: “the whole 
genetic area has been politicized by the concept of race.  While most geneticists 
would see ‘races’ merely as statistical entities representing higher than usual 
concentrations or of high proportion of certain configurations of genetic 
information, (Montagu, 1969) the general public does not share this view.”
 121  It is 
remarkable that Kalow continued to make the case for race in pharmacogenetics 
despite his awareness of Ashley Montagu’s critique of race. 
  These tensions appear in the careful rhetoric and inconsistencies seen in 
Kalow’s accounts of race in the 1970s into the 1980s.  During this time, Kalow 
shifted his focus from measuring the prevalence of atypical forms to deciphering   32   
specific biochemical pathways.  For instance, by studying the concentration of 
different metabolites in the urine of his research subjects, his team identified two 
distinct metabolic pathways for the barbiturate amobarbital and then, using twin 
studies, demonstrated a genetic basis.
122  In one typical study, Kalow recruited 144 
first-year medical students to ingest a fixed dose of amobarbital; 129 of them 
submitted urine samples at 36 hours.
123  The researchers studied metabolite levels 
to determine relative activity of two specific metabolic pathways, C-hydroxylation 
and N-glucosidation.  Most students exhibited twice as much hydroxylation as 
glucosidation (Figure 4).  Fourteen, however, had the opposite pattern.  These 
atypical students caught Kalow’s eye: “When preparing for the repeat investigations 
of students whose data seemed to be of particular interest, we were alerted by 
noting immediately and in succession some Chinese names among those with high 
N-glu excretion.”
124  Four of the fourteen students with atypical activity were 
Chinese, as compared to only six among the 115 others, a difference that was 
statistically significant. 
  Kalow interpreted this finding with an odd caution.  Even though he knew 
that “substantial racial or ethnic differences have been observed for the frequencies 
of all genes,” he professed uncertainty about whether the racial variation in 
amobarbital metabolism was “unique or whether it represents a more or less 
common phenomenon.”
125  Follow up studies confirmed the pattern.  While 10 of 
20 oriental students had this unusual pattern, only 1 of 20 Caucasian students did.  
Kalow strengthened his conclusion: “Thus, there is no doubt about a racial   33   
difference in the mix of amobarbital metabolites.”
126  As they continued to explore 
this question, Kalow’s team used a specific graphing technique, a probit plot 
(Figure 5), to transform overlapping Gaussian distributions (i.e., two overlapping 
bell curves) into distinct parallel lines.
127  This technique provided a starker visual 
argument for difference between groups.  But once again he remained cautious: 
“The racial differences in the appearance of amobarbital metabolites represent an 
observation at the descriptive level without any definite assignment of causes.  
While data collected among Caucasian twins and families suggested strongly that 
amobarbital elimination is under genetic control, such an observation made within 
one race does not prove a difference between races to be genetic.  It therefore, 
should be emphasized that we cannot distinguish with certainty between 
environmental and genetic causes for the observations reported here.  It 
nevertheless would be improper to dismiss the possibility of genetic 
interpretations.”
128 
  While working on amobarbital, Kalow also used other drugs as metabolic 
probes.  One, the antihypertensive debrisoquine, had been used by other 
researchers to reveal differences in a specific hydroxylation pathway between 
Britons and Kenyans.
129  He performed his own study of debrisoquine metabolism.  
He studied 51 students, of whom 13 were “Oriental (Chinese) origin” and found 
that the pattern of metabolites was “influenced by the ethnic origin of the 
subjects.”
130  This finding made sense: “ethnic differences definable by gene 
frequency occur in the cytochrome P-450 system as they do in all other, genetically   34   
controlled, drug-metabolizing enzyme systems.”
131  Yet despite his growing 
confidence reporting in racial differences, Kalow remained defensive: “The data 
described here were not originally collected for the purpose of studying ethnic 
differences.”
132  The ethnic difference “was discovered incidentally.”  Though wary 
about his small sample size, he reported the result because “the difference was 
statistically significant.”
 133 
  A third study, however, broke this pattern of racial findings.  Other 
researchers had found differences in antipyrine metabolism between white Britons 
living in London and Indians living in India.  Kalow recruited a sample of 48 
Caucasian and 19 Oriental students and measured antipyrine urine metabolites at 
48 hours.  This time he found no differences between the groups: “The 
fundamental similarity in antipyrine metabolism in the two populations is 
remarkable, because metabolite patterns of antipyrine differed significantly 
between subjects, and because the same two populations are known to differ much 
in their capacity for other drug oxidations.”
134  A parallel study, looking at 
antipyrine metabolism in rats, provided another surprise: “It must be noted that the 
metabolite profiles are remarkably similar in man and rat.”
135 
  Kalow’s writings in the late 1970s and early 1980s present a puzzle.  He 
described surprise when he found racial variations in amobarbital metabolism, and 
surprise when he did not find them for antipyrine (and even more surprise with the 
lack of human-rat differences).  When he reported his debrisoquine findings, he 
essentially apologized for doing so.  These narratives of surprise and apology   35   
suggest that Kalow experienced discomfort about his pursuit of a palpably 
politicized science.
136  As he had first done in the 1950s and 1960s, he emphasized 
specific narratives that served to naturalize the findings of difference. 
  First, he worked with other researchers as they mapped ethnic and racial 
difference in drug metabolism on a global scale.  They continued to find 
measurable differences whether they looked at the various cytochrome P-450 
systems or at cholinesterase, paraoxonase, or acetylation.
137  Second, he fit these 
data into the old evolutionary stories: “It should not surprise us to discover that the 
optimal structure of our biochemical defence systems is somewhat different in 
people of different regions of the world.  There are regional characteristics of flora 
and fauna, and hence there must be regional differences in naturally occurring 
toxic components of food or other environmental products.”
138  Third, he preserved 
the slippage in his work between species and races.  Commenting on the unusual 
extent of variation within human populations, Kalow noted that “Only a 
cosmopolitan species of brown bat seems to be genetically as diverse as are people 
within a given race.”
139 
  Kalow officially retired in 1982 but remained active in the field.  In 1985 he 
organized a major conference on racial and ethnic variations in drug metabolism 
that produced an influential collection of papers on the subject.
140  When the New 
England Journal of Medicine published a report on racial differences in propranolol 
metabolism, it recruited Kalow to write the accompanying editorial.  He took the 
opportunity to reiterate his old argument: “For the physician, the lesson of the Zhou   36   
study should be the importance of increased awareness of the possibility of 
differences in drug response and in dose requirements among patients from various 
ethnic and racial groups.”
141  He encouraged the World Health Organization and 
pharmaceutical companies to rise to this challenge: “The best scientific course for 
further action is to encourage systematic research to determine the factors, 
enzymes, and responses that tend to differ among the major races, and those that 
tend to be alike.”  As Kalow’s work slowed, others took the lead and published 
ever more studies of racial differences in drug metabolism,
142 and then reviews 
based on these new findings.
143  Researchers continued to slip easily between 
studies on specific populations, such as Swedes and Han Chinese, to conclusions 
about races, whether Caucasian or Oriental.
144 
  Controversies about race even reached Kalow late in his career.  By 2002 he 
had ceded lectures in the pharmacology course at the University of Toronto to his 
junior colleagues.  Each year the course included a routine lecture on 
pharmacogenetics that covered ethnic differences in drug effects between Africans, 
Asians, and Europeans.  In 2002, however, the students were outraged.  As Kalow 
wrote, “The professor was shocked to experience ugly protests by some students 
who called him ‘racist.’”
145  Kalow submitted an editorial to the local student 
newspaper, the Varsity, defending his colleague and the discussion of race: race 
was not a political issue, but simply a scientific one.  He also tried to make the case 
more widely.  Responding to a 2001 New England Journal of Medicine about the 
contested nature of race, he made his own case for why physicians ought to   37   
consider their patients’ racial and ethnic backgrounds.  The New England Journal 
rejected it without review.
146  He did succeed, however, in publishing a shortened 
defense of race in a specialty journal.
147 
 
Genetics and Other Possibilities 
  Even though genetics in general, and race in particular, have received 
increasing attention as popular explanations for inter-individual variation in drug 
response, they have existed in parallel with other explanations.  Recall that when 
Kalow was first assigned to the two cases of lethal reactions to procaine, his 
mentor, Hans Herken, had suggested that the problem was malnutrition.  As Kalow 
pursued genetics, other researchers focused on nutrition and other environmental 
influences.  In the early 1950s work on chemical carcinogenesis showed that 
specific drugs could influence the metabolism of other drugs, up- or down-
regulating drug metabolizing enzymes.
148  When the writings of Rachel Carson 
focused attention on environmental toxins, pharmacologists demonstrated how 
insecticides, including DDT, could induce the metabolism of drugs in humans.  By 
the early 1970s many inducers of drug metabolism had been found, including 
insecticides, herbicides, oils, aromatic hydrocarbons, dyes, nicotine, preservatives, 
plant alkaloids, xanthines, flavones, ozone, and carbon monoxide.
149 
  It was this work, grounded in biochemical pharmacology, that identified 
liver microsomal enzymes, especially the cytochrome P450 system, as an 
important site for drug metabolism.
150  A New York group even demonstrated that   38   
food, whether charcoaled steaks, cabbage, Brussels sprouts, or the Atkins diet 
could accelerate the metabolism of widely used drugs.
151  These studies found high 
rates of intra-individual variability: as research subjects changed their diet, smoking 
habits, or other environmental exposures over weeks or months, their drug 
metabolism shifted as well.
152  Drug metabolizing capacity was not a fixed 
characteristics of individuals.  Instead, it responded to individuals’ chemical 
environments.  Other studies found that apparent racial and ethnic differences, for 
instance between Londoners and Gambian or Sudanese villagers, also disappeared 
when diet and other environmental exposures were taken into consideration.
153 
  Kalow interacted with this environmental tradition throughout his career.  In 
the 1960s he participated in conferences with Brodie, Alan Conney, and many of 
the others who led the research on environmental factors that shaped drug 
metabolism.  As he wrote at the start of his 1962 Pharmacogenetics, “If this book 
stresses the existence of hereditary influences on pharmacologic response, this 
should not be taken as an attempt to minimize the importance of the effects of 
internal and external environment.  One may consider the total variation in the 
response to drugs as being caused by both hereditary and nonhereditary forces.”
154  
Later, during his work on amobarbital metabolism, he worried that the diverse food 
exposures of the increasingly diverse Toronto population might confound his 
findings: “If one looks at the Restaurant Guide in the yellow pages of the Toronto 
Telephone Directory, one finds captions indicating type of cuisine, stating 
alphabetically with American, Arabian, Armenian, Austrian, Chinese, Croatian,   39   
Cuban, Czechoslovakian, Danish, and so on, finishing with Vietnamese … It seems 
justified to assume that different people are routinely exposed to different enzyme 
inducers or toxic substances contained in their food and drinks.  Thus, we explicitly 
recognize that different people are exposed to different environments, and that life 
in the same city does not indicate exposure to the same environment.”
155  It 
made perfect sense to Kalow that the genetic and environmental traditions of drug 
metabolism research would co-exist.  They were, after all, linked by the familiar 
evolutionary narrative.  As animals evolved, they developed metabolic systems that 
could protect them from environmental chemicals and toxins.  Natural selection 
favored metabolic diversity that allowed organisms to adapt to changing 
environmental conditions.
156  Kalow knew that the genetic and adaptive 
components could be difficult to sort out: “Many studies with probe drugs 
comparing different populations have given results that are equivocal in terms of 
the nature-nurture interplay.”
157  He did not see this as a problem.  Instead, it was 
simply an appropriately complex reflection of a complex system: “All these 
observations provide a cautionary note against simplistic genetic or non-genetic 
interpretations of ethnic differences in metabolism data.”
158 
  From the 1950s into the 1990s, the research on the genetic and 
environmental determinants of drug response developed in parallel, often in 
synergy.  A third discourse also emerged, one that that emphasized the importance 
of non-compliance.
159  With estimates that a typical American patient takes only 
half of prescribed medications, non-compliance has a huge impact on serum drug   40   
levels.  This likely dwarfs most genetic and environmental factors and may be the 
most significant determinant of drug response and therapeutic effectiveness.  By the 
early 1990s, individual variability in treatment response was over-determined, with 
more explanations available than were usually needed to explain any particular 
unusual patient outcome.  The field may even have existed in a state of equipoise.  
Thinking back to my own years in medical school in the mid-1990s, I have clear 
memories of debates about the pejorative meanings of “non-compliant.”  The 
finding that grapefruit juice could interfere with commonly used antihypertensives 
received widespread attention.
160  I have no recollection of pharmacogenetics 
being discussed at all. 
  Then something changed.  As personalized medicine rose to prominence 
after 1999, physicians and entrepreneurs focused on genetic determinants of drug 
response.  By 2010, leading health officials essentially declared the equivalence of 
personalized medicine and genetic medicine.
161  Race-based medicine has 
followed closely on the heels of pharmacogenetics.
162  A 2001 review described 
racial variations in the response to many important medications, include ACE 
inhibitors, antipsychotics, ß-blockers, calcium channel blockers, chemotherapy 
agents, diuretics, insulin, interferon, morphine, steroids, vasodilators, and 
warfarin.
163  The potential of commercial innovation based on such differences is 
best demonstrated by the emergence of BiDil, a combination of two generic 
medications that were repackaged and approved for treatment of heart failure only 
in patients who self identify as black.
164  Critics have argued that the advent of BiDil   41   
simultaneously represents both a cynical exploitation of loopholes in patent law 
and FDA policy,
165 and our “durable preoccupation” with race.
166  Despite the 
drug’s commercial failure, there has been a “dramatic rise” since 2000 in 
biotechnology patents based on race and ethnicity.
167  Some products have already 
come to market.  Companies now sell race-specific vitamins, cosmetics, ancestry 
tests, and even walking shoes based on the putative unusual thickness of American 
Indian feet.
168  The shift in balance towards genetic and racial explanations poses a 
fundamental question: what determines the relative importance given to possible 
explanations of biomedical phenomena? 
  It is not hard to explain the factors that favored the emergence of 
pharmacogenetics in the 1990s.  Some operated at the broadest levels, with 
pharmacogenetics being but one example of the growing cultural fascination with 
all things genetic.
169  Others were more specific.  Sociologists have argued that the 
excited claims about expected future value have trumped concerns about cost and 
utility, such that researchers, regulators, investors, and patients all became 
enthusiastic despite lingering skepticism among clinicians.
170  The status of genetics 
in therapeutics parallels its status in disease theories, where it also receives ever 
greater emphasis despite general awareness of both the limited yields of genetic 
analysis to date and the importance of other factors to disease susceptibility.
171  
Pharmacogenetics, like genetic medicine more broadly, remains very much a 
promissory science.
172  More pragmatic factors have also played a role.  Genetic 
explanations are biologically justifiable and convenient.  The genetic sequence is   42   
seen as an invariant marker: measured once, it can guide treatment decisions 
throughout a patient’s life.  Genetic tests and technologies offer financial incentives 
not seen with interventions based on environmental exposures or non-compliance.  
Scientists seek funding, prestige, and marketable products through genetics.  
Regulators, investors, and patients encourage their pursuits. 
  Racial therapeutics have similarly strong appeals.  Even as genetics has 
offered new modes of affinity, they have often become aligned with pre-existing 
ideas about race and ethnicity.
173  Race-based practice is even more convenient 
than genetic practice: doctors need simply to look at a patient and profile 
accordingly.
174  The resurgence of racial medicine has triggered understandable 
concern.  Troy Duster, for instance, has warned that enthusiasm for genetics has 
led to the “molecular reinscription of race.”
175  Duana Fullwiley has described this 
in detail.  When the National Institutes of Health established its Pharmacogenetics 
Research Network in 2000, its stated goal was individualized medicine.  This soon 
gave way to a pragmatic and value-laden acceptance of race as a proxy for 
individual genetic variation.
176  In response to the concerns, many advocates of 
pharmacogenetics and other forms of racial medicine reassure themselves by 
arguing that the use of race will be just a passing phase on the road to fully 
individualized treatment.
177  However, the long presence of race in 
pharmacogenetics and the enduring popularity of race as a concept in science and 
society more generally suggest that its appeals will not fade quickly.  The continued   43   
presence of race in medical practice will require on-going scrutiny from medical 
and social scientists.
178 
  Even amid these many factors that facilitated the emergence of a racialized 
pharmacogenetics in the 1990s and 2000s, an appreciation of the longer history of 
the field deepens our understanding.  Kalow’s work began at a time when genetics 
did not preoccupy our worldview, before entrepreneurs had begun to funnel 
venture capital into the field, and before claims of the general relevance of 
pharmacogenetic alleles could even be attempted.  Despite that, he had access to 
many strategies.  Pharmacologic technology, from dibucaine numbers to the 
rhetorical power of probit plots, allowed him to craft simple but powerful 
arguments about the reality of difference and its genetic correlates.  Analogies to 
differences between species and subspecies provided precedents for the 
expectation that human racial differences would exist.  Appeals to the logic of 
natural selection explained why drug-metabolizing variants might have found their 
way into our genomes.  A few cases, such as the distribution of isoniazid side 
effects seen in global tuberculosis campaigns or the terror of malignant 
hyperthermia, demonstrated the potential relevance of pharmacogenetics for health 
care and health policy.  Once the claims were made by Kalow and others that 
pharmacogenetics was real and relevant, they had consequences: pharmacologists 
came to expect that genetic and racial variations would exist and they searched for 
them in what became a self-fulfilling prophecy.
179  Kalow’s work, along with that of 
Motulsky, Vesell, and others opened up the niche for pharmacogenetics and,   44   
within that, for race.  This established a foundation of expectations on which later 
advocates could build their pharmacogenetic promises. 
  An appreciation of this history also alerts us to ways to broaden the 
discourse about personalized medicine.  Seen in the longest perspective, the 
standardization of medical practice enabled by the model of specific etiology and 
specific therapy relied on an over-simplification (i.e., that all patients with a given 
disease could be treated in the same fashion), but one that brought vast gains in 
efficiency and increased the access of the world’s populations to powerful 
treatments.  The move is now away from standardization back towards 
individualization.  But pharmacogenetics is another over-simplification.  Focus on 
genetics leads to the neglect of other variables that influence drug response.  In 
contrast to the dramatic scientific and commercial interest in pharmacogenetics, 
there is no similar energy for other ways of personalizing medicine.  Where are the 
reviews or products that would help doctors assess diet and other environmental 
determinants of drug response?  Where are the calls to understand patients’ lives in 
a way that might allow physicians to prescribe feasible treatment plans?  The rare 
exceptions that do exist demonstrate the potential power of social approaches to 
improve treatment outcome.
180 
  Some observers have recently begun to suggest that the genetic moment has 
passed.
181  Motulsky himself admitted in a New York Times profile that “the 
promise of pharmacogenetics is sometimes overhyped. There are people who think 
we’ll be able to solve almost everything with an individualized prescription. We   45   
need more research, which will be expensive.”
182 Excitement has moved from 
genetics and genomics to epigenetics, proteomics, metabolonomics, and even 
microbiomics.  It should also be possible to expand discussions of personalized 
medicine to include environment and behavior.  Past experience suggests that 
genetics and race will both endure in medical practice, entrenched as they are in 
science, governance, and social relations. The promises and hopes that continue to 
circulate, however, deserve to be tempered by the many insights that can be 
gleaned from the history of pharmacogenetics. 
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